Compugen Obtains Rights to Use Biological Systems and Materials from the US National Institutes of Health
April 14 2015 - 7:02AM
Business Wire
Additional capabilities anticipated to
enhance research and development of Compugen’s immuno-oncology
programs
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug
discovery company, today announced that it has obtained rights to
use in-house certain biological systems and materials, developed by
the U.S. National Institutes of Health (NIH), for purposes of
advancing the research and development of the Company’s multiple
immuno-oncology programs toward future clinical evaluation.
The experimental systems and biological materials obtained from
the NIH enable the engineering of human T cells to specifically
recognize tumor antigens on cancer cells. Utilizing this system,
with the expression of specific Compugen-discovered immune
checkpoint candidates on the surface of human cancer cells, or
immune T cells, will strengthen Compugen’s evaluation abilities of
the effect of such immune checkpoints on anti-tumor immune
response. The NIH biological systems and materials are expected to
facilitate robust and reproducible validation of Compugen’s
multiple immune checkpoint target candidates and to enhance the
identification of functional therapeutic antibodies and selection
of lead antibodies for future clinical evaluation.
Dr. Anat Cohen-Dayag, President and Chief Executive Officer of
Compugen, stated, “We are pleased to have access to these robust
experimental systems and materials developed by NIH scientists,
which will enhance our immuno-oncology capabilities and enable
extensive testing of human antibodies. In addition, Compugen has
obtained the right from the NIH to utilize a cell line that will
allow the use of tumor syngeneic models that will also serve as
part of Compugen’s suite of preclinical studies. Together with our
recent collaboration with Johns Hopkins University, these new
capabilities provide us with a broader base to swiftly advance in
parallel multiple immune checkpoint programs toward the development
of first-in-class biologics.”
About Compugen
Compugen is a leading predictive drug discovery company focused
on monoclonal antibodies and therapeutic proteins to address
important unmet needs in the fields of oncology and
immunology. The Company utilizes a broad and continuously
growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine
learning systems and other computational biology capabilities for
the in silico (by computer) prediction and selection of
novel drug target candidates, which are then advanced in its
Pipeline Program. The discovery and development of monoclonal
antibody therapeutic candidates against selected
Compugen-discovered novel target candidates is performed by
Compugen’s wholly-owned US subsidiary located in South San
Francisco. The Company's business model includes collaborations
covering the further development and commercialization of product
candidates at various stages from its Pipeline Program and various
forms of research and discovery agreements, in both cases providing
Compugen with potential milestone payments and royalties on product
sales or other forms of revenue sharing. For additional
information, please visit Compugen's corporate website at
www.cgen.com.
Forward Looking Statement This press release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of terminology such as
“will,” “may,” “expects,” “anticipates,” “believes,” and “intends,”
and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that
may cause the actual results, performance or achievements of
Compugen to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Some of these risks include: that
Compugen’s business model is substantially dependent on entering
into collaboration agreements with third parties and may not be
successful in generating revenues, and that the development and
commercialization of therapeutic products includes many inherent
risks, including failure to receive regulatory approval. These and
other factors are more fully discussed in the "Risk Factors"
section of Compugen’s most recent Annual Report on Form 20-F as
filed with the Securities and Exchange Commission as well as other
documents that may be subsequently filed by Compugen from time to
time with the Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media
Liaisontsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024